Search

Your search keyword '"Hasford, J"' showing total 414 results

Search Constraints

Start Over You searched for: Author "Hasford, J" Remove constraint Author: "Hasford, J" Language english Remove constraint Language: english
414 results on '"Hasford, J"'

Search Results

3. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

6. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

8. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries

10. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib

11. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV

13. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment

14. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study

23. The German competence network ‘Acute and chronic leukemias’

26. Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon α and hydroxyurea

31. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

32. Data from the German-Austrian-Suisse MDS registry (D-A-CH MDS registry): V954

34. Superior CMR-rates with tolerability-adapted imatinib 800 mg vs. 400 mg vs. 400 mg + IFN in CML: The randomized German CML-Study IV: V633

35. Therapy with imatinib in elderly CML patients (≥65 years): Results of the German CML-Study IV: V632

39. Optimization of imatinib therapy by combination. Final results of the pilot phase of the randomized German CML Study IV: V279

40. High dose imatinib 800mg induces higher major molecular response (MMR) rates than imatinib 400 mg ± IFN in newly diagnosed BCR/ABL positive chronic phase CML: A randomized comparison of the German CMLStudy IV: V276

41. Evolution of blast crisis (BC) in chronic myeloid leukemia (CML) in the imatinib-era: A rare but early event; need for rapid detection. Results of the German CML Study IV.: V281

43. Optimization of Imatinib Therapy By Combination. 5 Year Survival and Response; Results of the Pilot Phase of the Randomized German CML Study IV: FV326

44. OPTIMIZATION OF IMATINIB THERAPY BY COMBINATION, DOSE ESCALATION AND TRANSPLANTATION. DESIGNED FIRST INTERIM ANALYSIS OF THE RANDOMIZED GERMAN CML STUDY IV: V54

45. Allogeneic hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML) in the imatinib era: Evaluation of its impact within a subgroup of the German CML Study IV: V56

46. Early Molecular Response to First Line Imatinib Therapy Is Predictive for Long Term PFS and EFS in CP-CML - an Interim Analysis of the Randomized German CML Study IV.: V55

Catalog

Books, media, physical & digital resources